Literature DB >> 22193411

Clinical chemistry of human FcRn transgenic mice.

Carsten Stein1, Lothar Kling, Gabriele Proetzel, Derry C Roopenian, Martin Hrabě de Angelis, Eckhard Wolf, Birgit Rathkolb.   

Abstract

Mice genetically engineered to express human FcRn are valuable models for the evaluation of therapeutic antibodies in the context of human FcRn in vivo. However, only limited clinical chemistry information on these mouse strains is available. Thus, we have compared 30 clinical chemical parameters of C57BL/6J wild-type mice, murine FcRn-knockout mice, and two human FcRn transgenic mouse strains expressing human FcRn in the absence of murine FcRn. Since FcRn-mediated recycling prevents albumin and IgG from intracellular degradation, significant differences for both proteins were observed in the murine FcRn-knockout mice. Mice lacking FcRn show lower IgG and albumin levels compared to wild-type mice. The most prominent differences in clinical chemical parameters can be explained by secondary effects of the altered albumin levels of murine FcRn-knockout mice on liver metabolism, as similar tendencies have been observed in analbuminemic Nagase rats and hypoalbuminemic human patients, showing an overall increased liver metabolism. Both human FcRn transgenic strains show clinical chemical parameters similar to those found for wild-type mice, with the exception of endogenous IgG levels, which are greatly reduced in these mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193411     DOI: 10.1007/s00335-011-9379-6

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  72 in total

1.  Hyperparathyroidism is augmented by ovariectomy in Nagase analbuminemic rats.

Authors:  M Inaba; H Morii; T Katsumata; H Goto; E Ishimura; T Kawagishi; M Kamao; T Okano; Y Nishizawa
Journal:  J Nutr       Date:  2000-06       Impact factor: 4.798

2.  A novel splicing mutation causes an undescribed type of analbuminemia.

Authors:  Monica Campagnoli; Antonio Rossi; Lars Palmqvist; Anders Flisberg; Aimon Niklasson; Lorenzo Minchotti; Monica Galliano
Journal:  Biochim Biophys Acta       Date:  2002-01-02

3.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

4.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

5.  Effects of hypercapnia on BP in hypoalbuminemic and Nagase analbuminemic rats.

Authors:  Jose L Gómez; Kyle J Gunnerson; Mingchen Song; Jinyou Li; John A Kellum
Journal:  Chest       Date:  2007-05       Impact factor: 9.410

6.  Systemic first-line phenotyping.

Authors:  Valérie Gailus-Durner; Helmut Fuchs; Thure Adler; Antonio Aguilar Pimentel; Lore Becker; Ines Bolle; Julia Calzada-Wack; Claudia Dalke; Nicole Ehrhardt; Barbara Ferwagner; Wolfgang Hans; Sabine M Hölter; Gabriele Hölzlwimmer; Marion Horsch; Anahita Javaheri; Magdalena Kallnik; Eva Kling; Christoph Lengger; Corinna Mörth; Ilona Mossbrugger; Beatrix Naton; Cornelia Prehn; Oliver Puk; Birgit Rathkolb; Jan Rozman; Anja Schrewe; Frank Thiele; Jerzy Adamski; Bernhard Aigner; Heidrun Behrendt; Dirk H Busch; Jack Favor; Jochen Graw; Gerhard Heldmaier; Boris Ivandic; Hugo Katus; Martin Klingenspor; Thomas Klopstock; Elisabeth Kremmer; Markus Ollert; Leticia Quintanilla-Martinez; Holger Schulz; Eckhard Wolf; Wolfgang Wurst; Martin Hrabé de Angelis
Journal:  Methods Mol Biol       Date:  2009

Review 7.  Analbuminemia: report of a case and review of the literature.

Authors:  F Dammacco; A Miglietta; A D'Addabbo; A Fratello; R Moschetta; L Bonomo
Journal:  Vox Sang       Date:  1980-09       Impact factor: 2.144

8.  Hypertriacylglycerolemia and adipose tissue lipoprotein lipase activity in the Nagase analbuminemic rat.

Authors:  H Kikuchi; S Tamura; S Nagase; S Tsuiki
Journal:  Biochim Biophys Acta       Date:  1983-04-28

9.  Genetic background determines metabolic phenotypes in the mouse.

Authors:  Marie-France Champy; Mohammed Selloum; Valérie Zeitler; Claudia Caradec; Barbara Jung; Stéphane Rousseau; Laurent Pouilly; Tania Sorg; Johan Auwerx
Journal:  Mamm Genome       Date:  2008-04-05       Impact factor: 2.957

10.  Increased cholesteryl ester transfer activity in plasma from analbuminemic patients.

Authors:  S Braschi; L Lagrost; E Florentin; C Martin; A Athias; P Gambert; M Krempf; C Lallemant; B Jacotot
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-03       Impact factor: 8.311

View more
  14 in total

1.  Neonatal Fc receptor promotes immune complex-mediated glomerular disease.

Authors:  Florina Olaru; Wentian Luo; Hani Suleiman; Patricia L St John; Linna Ge; Adam R Mezo; Andrey S Shaw; Dale R Abrahamson; Jeffrey H Miner; Dorin-Bogdan Borza
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

2.  Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.

Authors:  Susan H Tam; Stephen G McCarthy; Kerry Brosnan; Kenneth M Goldberg; Bernard J Scallon
Journal:  MAbs       Date:  2013-04-02       Impact factor: 5.857

Review 3.  Genetically engineered humanized mouse models for preclinical antibody studies.

Authors:  Gabriele Proetzel; Michael V Wiles; Derry C Roopenian
Journal:  BioDrugs       Date:  2014-04       Impact factor: 5.807

4.  Considerations for Generating Humanized Mouse Models to Test Efficacy of Antisense Oligonucleotides.

Authors:  Irene Vázquez-Domínguez; Alejandro Garanto
Journal:  Methods Mol Biol       Date:  2022

5.  Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.

Authors:  Gabriele Proetzel; Derry C Roopenian
Journal:  Methods       Date:  2013-07-16       Impact factor: 3.608

6.  Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs.

Authors:  Derry C Roopenian; Benjamin E Low; Gregory J Christianson; Gabriele Proetzel; Thomas J Sproule; Michael V Wiles
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  A human endothelial cell-based recycling assay for screening of FcRn targeted molecules.

Authors:  Algirdas Grevys; Jeannette Nilsen; Kine M K Sand; Muluneh B Daba; Inger Øynebråten; Malin Bern; Martin B McAdam; Stian Foss; Tilman Schlothauer; Terje E Michaelsen; Gregory J Christianson; Derry C Roopenian; Richard S Blumberg; Inger Sandlie; Jan Terje Andersen
Journal:  Nat Commun       Date:  2018-02-12       Impact factor: 14.919

8.  M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

Authors:  Leona E Ling; Jan L Hillson; Renger G Tiessen; Tjerk Bosje; Mattheus Paulus van Iersel; Darrell J Nix; Lynn Markowitz; Nicholas A Cilfone; Jay Duffner; James B Streisand; Anthony M Manning; Santiago Arroyo
Journal:  Clin Pharmacol Ther       Date:  2018-12-04       Impact factor: 6.875

9.  An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.

Authors:  Chang-Han Lee; Tae Hyun Kang; Ophélie Godon; Makiko Watanabe; George Delidakis; Caitlin M Gillis; Delphine Sterlin; David Hardy; Michel Cogné; Lynn E Macdonald; Andrew J Murphy; Naxin Tu; Jiwon Lee; Jonathan R McDaniel; Emily Makowski; Peter M Tessier; Aaron S Meyer; Pierre Bruhns; George Georgiou
Journal:  Nat Commun       Date:  2019-11-06       Impact factor: 14.919

10.  Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.

Authors:  Jan Terje Andersen; Stian Foss; Vania E Kenanova; Tove Olafsen; Ingvild S Leikfoss; Derry C Roopenian; Anna M Wu; Inger Sandlie
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.